Abstracts
Background Acinetobacter baumannii is a multidrug-resistant bacterium responsible for severe infections, particularly in hospital settings. Its resistance is driven by enzymatic genes such as those encoding beta-lactamases and carbapenemases, which degrade antibiotics, and non-enzymatic genes that modify mechanisms like efflux pumps and membrane permeability, further enhancing its defence against treatments. Together, these factors allow A. baumannii to thrive in clinical environments, complicating infection management.
Objective This study aimed to explore the relationships between beta-lactamases, carbapenemases, efflux pumps, and membrane permeability changes, to understand their collective contribution to A. baumannii’s multidrug resistance.
Materials and Methods Among 300 clinical isolates from urine, blood, wounds, and burns, 25 (8.33%) were identified as A. baumannii. These included 8% from urine, 12% from blood, and 40% each from wound and burn swabs. all specimens were taken from patients who have different symptoms in hospital of Al-Hilla Teaching Hospital/ Babylon. The research was carried out through the period January and June 2024. Bacterial identification was conducted using the VITEK-2 system and HI-Chromoagar® A. baumannii. Enzymatic genes were detected using conventional PCR, while non-enzymatic genes were analyzed via RT-qPCR.
Results Molecular analysis revealed the presence of beta-lactamase (blaOXA-51, blaOXA-23) and metallo-beta-lactamase genes (blaVIM, blaIMP), with high antibiotic resistance rates. Gene expression analysis highlighted efflux pump upregulation (adeB) and altered permeability (CarO), reinforcing multidrug resistance mechanisms.
Conclusion The combined action of enzymatic and non-enzymatic resistance genes in A. baumannii presents a significant treatment challenge, necessitating multi-target therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
all specimens were taken from patients who have different symptoms in hospital of Al-Hilla Teaching Hospital/ Babylon
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the ethical committee at Hilla Surgical Teaching Hospital. Furthermore, all individuals participating in the study were informed about the research, and their consent for both conducting the experiments and publishing the results was obtained prior to sample collection. This study was also approved by a local ethics committee at the College of Medicine, University of Babylon. and hospital ethics committee under document number [ IRB: 4-27, 3/1/2024].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
clinical isolates from urine, blood, wounds, and burns,
